Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Basic Medicine
  4. Vol 1, Issue 2, 2023

The Most Promising Targeted Preparation for the Treatment of Migraine from the Pathophysiological Mechanism: Aimed at CGRP Drugs

Download as PDF

DOI: 10.23977/medbm.2023.010213 | Downloads: 14 | Views: 326

Author(s)

Xinyi Cui 1, Hai Lin 1

Affiliation(s)

1 First Clinical Hospital, Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China

Corresponding Author

Hai Lin

ABSTRACT

Migraine is a common disorder of brain dysfunction. At present, there are four theories: trigeminal neurovascular theory, vascular dysfunction theory, neurogenic inflammation theory, and diffusion inhibition theory, which provide new ideas for the treatment of migraine. In recent years, the study of CGRP (calcitonin gene-related peptide) receptor antagonists and CGRP-targeted antibodies has made breakthroughs in the treatment of migraine. By blocking or inhibiting the effects of CGRP, these drugs can effectively reduce the attack frequency and pain degree of migraine, with good efficacy and safety. New migraine prophylactic drugs, such as CGRP receptor monoclonal antibodies and small molecule CGRP receptor antagonists have been developed and approved, and some anti-CGRP drugs have shown good efficacy and safety in clinical trials, making anti-CGRP drugs a new and effective clinical treatment for migraine, providing more options and hope for the treatment of migraine. This paper explores the mechanism of action, efficacy and safety of anti-CGRP drugs. With the continuous development of science and technology, it is believed that more drugs will appear in the future, bringing more treatment options for migraine patients.

KEYWORDS

Monoclonal Antibody, CGRP, Calcitonin Gene-related Peptide, Migraine Trigeminovascular System

CITE THIS PAPER

Xinyi Cui, Hai Lin, The Most Promising Targeted Preparation for the Treatment of Migraine from the Pathophysiological Mechanism: Aimed at CGRP Drugs. MEDS Basic Medicine (2023) Vol. 1: 79-88. DOI: http://dx.doi.org/10.23977/medbm.2023.010213.

REFERENCES

[1] Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: from pathophysiology to treatment. J Neurol. 2023 Jul; 270(7):3654-3666. doi: 10.1007/s00415-023-11706-1. Epub 2023 Apr 8. PMID: 37029836; PMCID: PMC10267278.
[2] Pleș H, Florian IA, Timis TL, Covache-Busuioc RA, Glavan LA, Dumitrascu DI, Popa AA, Bordeianu A, Ciurea AV. Migraine: Advances in the Pathogenesis and Treatment. Neurol Int. 2023 Aug 31;15(3):1052-1105. doi: 10.3390/neurolint15030067. PMID: 37755358; PMCID: PMC10535528.
[3] Gawde P, Shah H, Patel H, Bharathi KS, Patel N, Sethi Y, Kaka N. Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium. Cureus. 2023 Feb 2;15(2):e34553. doi: 10.7759/cureus.34553. PMID: 36879707; PMCID: PMC9985459.
[4] Blair HA. Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine. CNS Drugs. 2023 Mar;37(3):255-265. doi: 10.1007/s40263-023-00988-8. Epub 2023 Feb 4. Erratum in: CNS Drugs. 2023 Jul;37(7):661. PMID: 36739335; PMCID: PMC10299922.
[5] Silvestro M, Iannone LF, Orologio I, Tessitore A, Tedeschi G, Geppetti P, Russo A. Migraine Treatment: Towards New Pharmacological Targets. Int J Mol Sci. 2023 Jul 31;24(15):12268. doi: 10.3390/ijms241512268. PMID: 37569648; PMCID: PMC10418850.
[6] Cohen F, Yuan H, DePoy EMG, Silberstein SD. The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine. Neurotherapeutics. 2022 Apr;19(3):922-930. doi: 10.1007/s13311-022-01230-x. Epub 2022 Apr 14. PMID: 35426060; PMCID: PMC9294119.
[7] Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache. 2019 May;59(5):659-681. doi: 10.1111/head.13529. Epub 2019 Apr 14. PMID: 30982963; PMCID: PMC6593989.
[8] Lambru G, Andreou AP, Guglielmetti M, Martelletti P. Emerging drugs for migraine treatment: an update. Expert Opin Emerg Drugs. 2018 Dec;23(4):301-318. doi: 10.1080/14728214.2018.1552939. Epub 2018 Nov 30. PMID: 30484333.
[9] Blair HA. Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine. CNS Drugs. 2023 Mar;37(3):255-265. doi: 10.1007/s40263-023-00988-8. Epub 2023 Feb 4. Erratum in: CNS Drugs. 2023 Jul;37(7):661. PMID: 36739335; PMCID: PMC10299922.
[10] Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019 Jan;25(2 Suppl):S23-S34. PMID: 30681821.
[11] de Boer I, Verhagen IE, Souza MNP, Ashina M. Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia. 2023 Feb;43(2):3331024221143773. doi: 10.1177/03331024221143773. PMID: 36739516.
[12] Lee MJ, Al-Karagholi MA, Reuter U. New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy. Cephalalgia. 2023 Feb;43(2):3331024221146315. doi: 10.1177/03331024221146315. PMID: 36759320.
[13] Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L'Italien G, Morris BA, Coric V, Goadsby PJ. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. Cephalalgia. 2023 Feb;43(2):3331024221141686. doi: 10.1177/03331024221141686. PMID: 36739511.
[14] Ailani J, Lipton RB, Hutchinson S, Knievel K, Lu K, Butler M, Yu SY, Finnegan M, Severt L, Trugman JM. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. Headache. 2020 Jan;60(1):141-152. doi: 10.1111/head.13682. Erratum in: Headache. 2021 Jun;61(6):978-981. PMID: 31913519; PMCID: PMC7004213.
[15] Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018 Jul;38(8):1442-1454. doi: 10.1177/0333102418779543. Epub 2018 May 31. PMID: 29848108.
[16] Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853. PMID: 29800211; PMCID: PMC6583237.
[17] Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain. 2020 Oct 6;21(1):120. doi: 10.1186/s10194-020-01186-3. PMID: 33023473; PMCID: PMC7539382.
[18] Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 May;38(6):1026-1037. doi: 10.1177/0333102418759786. Epub 2018 Feb 22. PMID: 29471679.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 431
Visits: 13470

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.